fibro-vein 30 mg/ml oldatos injekció
std pharmaceutical (ireland) ltd. - a nátrium-tetradecil-szulfát -
fibro-vein 10 mg/ml oldatos injekció
std pharmaceutical (ireland) ltd. - a nátrium-tetradecil-szulfát -
daivobet 50 mikrogramm/0,5 mg/g kenőcs
leo pharma a/s - calcipotriol; betamethasone -
fibro-vein 5 mg/ml oldatos injekció
std pharmaceutical (ireland) ltd. - a nátrium-tetradecil-szulfát -
suiseng coli / c szuszpenziós injekció sertéseknek
laboratorios hipra s.a. - clostridium novyi, escherichia coli, clostridium perfringens - szuszpenziós injekció - escherichia vaccine + clostridium vaccine - sertés
dexamethasone kalceks 4 mg/ml oldatos injekció vagy infúzió
as kalceks - dexametazon-nátrium-foszfát -
gemcitabine accord 200 mg por oldatos infúzióhoz
accord healthcare polska sp. z o.o. - a gemcitabin -
gemcitabine accord 1 g por oldatos infúzióhoz
accord healthcare polska sp. z o.o. - a gemcitabin -
gemcitabine accord 2 g por oldatos infúzióhoz
accord healthcare polska sp. z o.o. - a gemcitabin -
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - daganatellenes szerek - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).